Eli Lilly's LY4268989 Study with Mirikizumab in Ulcerative Colitis Underway
A clinical trial is evaluating the safety and effectiveness of LY4268989 co-administered with mirikizumab in adults with moderately to severely active ulcerative colitis.
Therapeutic Area
Therapeutic area intelligence for Gastroenterology with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.